Characterisation of genome-wide structural aberrations in canine mammary tumours using single nucleotide polymorphism (SNP) genotyping assay
- PMID: 30997777
- DOI: 10.24425/pjvs.2019.127080
Characterisation of genome-wide structural aberrations in canine mammary tumours using single nucleotide polymorphism (SNP) genotyping assay
Abstract
Characterisation of copy number variation (CNV) and loss of heterozygosity (LOH) has pro- vided evidence for the relationship of this type of genetic variation with the occurrence of a broad spectrum of diseases, including cancer lesions. The role of CNVs and germinal or somatic LOHs in canine mammary tumours is still unknown. Therefore, the aim of this study was to identify CNVs and LOHs in canine mammary tumours. Forty-eight samples obtained from normal (n=24) and tumour (n=24) tissues of dogs were analysed. In the study, we used CanineHD BeadChip assay (Illumina) and OncoSNP software to identify copy number alternations in genomes of dif- ferent dog breeds and in different mammary cancer types occurring in this species. The analyses revealed that, in the case of CNV, the amplification-type variants were longer and more frequent than deletions. Based on the analysis of the frequency of different types of aberrations in the in- dividual parts of the genome, regions that are particularly susceptible to structural aberrations were indicated. The fraction of genes identified within these regions was associated with major processes of neoplastic transformation. Association analysis of such traits as tumour grading as well as the size and age of dogs demonstrated that structural aberrations were more frequent in dogs diagnosed with tumour malignancy grade II and III, in dogs with a larger body size, and in large dogs aged 7-8. The promising results of these pioneering investigations prompt continuation thereof to analyse other types of cancer.
Keywords: CNV; LOH; cancer; dog; mammary tumour; structural aberration.
Copyright© by the Polish Academy of Sciences.
Similar articles
-
Canine Mammary Tumours Are Affected by Frequent Copy Number Aberrations, including Amplification of MYC and Loss of PTEN.PLoS One. 2015 May 8;10(5):e0126371. doi: 10.1371/journal.pone.0126371. eCollection 2015. PLoS One. 2015. PMID: 25955013 Free PMC article.
-
Defect of the mitochondrial DNA hypervariable region as a risk factor for canine mammary tumour.Vet Comp Oncol. 2017 Sep;15(3):820-828. doi: 10.1111/vco.12224. Epub 2016 May 19. Vet Comp Oncol. 2017. PMID: 27198058
-
Increased survival in dogs with malignant mammary tumours overexpressing HER-2 protein and detection of a silent single nucleotide polymorphism in the canine HER-2 gene.Vet J. 2009 Apr;180(1):116-23. doi: 10.1016/j.tvjl.2007.10.013. Epub 2007 Dec 3. Vet J. 2009. PMID: 18061495
-
Mutations of BRCA2 in canine mammary tumors and their targeting potential in clinical therapy.BMC Vet Res. 2020 Jan 31;16(1):30. doi: 10.1186/s12917-020-2247-4. BMC Vet Res. 2020. PMID: 32005245 Free PMC article. Review.
-
Advances in the understanding of the clinically relevant genetic pathways and molecular aspects of canine mammary tumours: part 1. Proliferation, apoptosis and DNA repair.Vet J. 2015 Aug;205(2):136-43. doi: 10.1016/j.tvjl.2015.02.004. Epub 2015 Feb 11. Vet J. 2015. PMID: 25744808 Review.